Baird Medical Investment Holdings vs Sonoma Pharmaceuticals
Baird Medical Investment Holdings is the larger business, with $22.5m of revenue in fiscal 2025 against $19.5m for Sonoma Pharmaceuticals (1.2 times as much). Sonoma Pharmaceuticals grew faster (36.7% against -39.2%). Sonoma Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -16.3% against -121.0%.
| Latest fiscal year | Baird Medical Investment HoldingsBDMD, 2025 | Sonoma PharmaceuticalsSNOA, 2026 |
|---|---|---|
| Revenue | $22.5m | $19.5m |
| Revenue growth | -39.2% | 36.7% |
| Net income | −$27.3m | −$3.2m |
| Operating margin | -113.7% | — |
| Net margin | -121.0% | -16.3% |
| Return on equity | -76.8% | -84.6% |
| Free cash flow | −$1.4m | −$4.1m |
| Cash | $178,321 | $2.4m |
| Total debt | $8.7m | $222,000 |
| Debt to equity | 27.8% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 9 |
| Market value | $3.3m | $5.5m |
| Price vs our value range | — | — |
| Moat score | — | 26 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |